Journal of NeuroVirology

, Volume 24, Issue 5, pp 642–646 | Cite as

Meningomyeloradiculitis following yellow fever 17D vaccination: a case report

  • Rody El Nawar
  • Perrine Bayle
  • Andrei Girbovan
  • Stephanie Juillet Marque
  • Jerome Servan
  • Fernando Pico
Case Report


The yellow fever 17D vaccine contains live-attenuated virus. Initial efficacy and safety reports were favorable. Recently, however, neurologic and viscerotropic adverse events (AE) were described. We managed a 61-year-old man who experienced meningomyeloradiculitis 18 days after receiving the yellow fever 17D vaccine. The manifestations were atypical. The cerebrospinal fluid contained high titers of anti-yellow fever immunoglobulins M and G and of anti-flavivirus immunoglobulins G. After methylprednisolone (1 g/day for 3 days), intravenous human immunoglobulins (140 g over 5 days), and two plasma exchanges, the symptoms improved only slightly. Neurological adverse events after yellow fever vaccination are rare or underestimated. To our knowledge, this is the first reported case of meningomyeloradiculitis after yellow fever vaccination. A remarkable feature is the intrathecal production of yellow fever antibodies, which probably played a pathogenic role and may have been related to a recent episode of influenza.


Vaccine Neuroimmunology Virology Meningomyeloradiculitis Yellow fever 



We thank Dr. Isabelle Leparc-Goffart, PhD, HDR and the National Arbovirus Reference Center, Laveran Hospital, Marseille, France, for the support and advice and the Centre Hospitalier de Versailles for the editorial assistance.

The manuscript has not been published previously and is not being considered for publication elsewhere.

Compliance with ethical standards


The patient gave written informed consent to publication of this case report and of any accompanying photographs, under condition of anonymity.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Hayes EB (2010) Is it time for a new yellow fever vaccine? Vaccine 28:8073–8076CrossRefGoogle Scholar
  2. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS, Yellow Fever Vaccine Safety Working Group (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23:3256–3263CrossRefGoogle Scholar
  3. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB (2008) Adverse event reports following yellow fever vaccination. Vaccine 26:6077–6082CrossRefGoogle Scholar
  4. Marfin AA, Eidex RS, Kozarsky PE, Cetron MS (2005) Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin N Am 19:151–168CrossRefGoogle Scholar
  5. Martins RM, Pavao AL, de Oliveira PM, dos Santos PR, Carvalho SM, Mohrdieck R, Fernandes AR, Sato HK, de Figueiredo PM, von DoellingerVdos R, Leal Mda L, Homma A, Maia Mde L (2014) Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine 32:6676–6682CrossRefGoogle Scholar
  6. Vasconcelos PF (2003) Yellow fever. RevSocBrasMed Trop 36:275–293Google Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2018

Authors and Affiliations

  • Rody El Nawar
    • 1
    • 2
  • Perrine Bayle
    • 3
  • Andrei Girbovan
    • 1
  • Stephanie Juillet Marque
    • 4
  • Jerome Servan
    • 1
  • Fernando Pico
    • 1
    • 5
  1. 1.Department of Neurology and Stroke CenterCentre Hospitalier de VersaillesVersaillesFrance
  2. 2.Gilbert and Rose-Marie Chagoury School of MedicineLebanese American UniversityBeirutLebanon
  3. 3.Department of Internal Medicine and Infectious DiseasesCentre Hospitalier de VersaillesLe ChesnayFrance
  4. 4.Department of BiologyCentre Hospitalier de VersaillesLe ChesnayFrance
  5. 5.Université Versailles Saint-Quentin en Yvelines et Paris SaclayVersaillesFrance

Personalised recommendations